Moderna, Inc. - Common Stock (MRNA)

The stock fell 17% in one trading session.

Investors who lost money on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation follows the October 22, 2026 disclosure regarding Moderna, Inc.

Investors who suffered losses on Moderna, Inc. ("Moderna" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Moderna, Inc. (NASDAQ: MRNA) investors into whether the Company may have violated the federal securities laws. The investigation comes after a October 22, 2026 disclosure concerning Moderna, Inc.

CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.

Personalized cancer vaccine material allegedly circulated online ahead of formal Phase 3 results, today, Oct. 22, 2026.

What happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 22.7% in the afternoon session after the company's partial Phase 3 data for its per...

Moderna, Inc. ("Moderna" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in Moderna, Inc. (NASDAQ: MRNA), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about Moderna, Inc. on October 22, 2026.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as adjuvant treatment for patients with completely resected stage IIB-IV melanoma. These late-breaking results will be presented for the first time during Presidential Symposium I at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation #LBA1), were selected for an official ESMO Press Briefing and have been accepted for publication in The New England Journal of Medicine.

The market has rewarded this biotech for its breakthroughs.

This company made headlines with its coronavirus vaccine.

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

What Happened? A number of stocks jumped in the afternoon session after investors rotated into defensive assets and priced in rising expectations that midter...

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

It has been a volatile year for the biotech.

It was a head-turning headline. Here's why the market was buzzing.

Sandisk is changing its business model to reduce its cyclicality.

Momentum is only half the battle. Their underlying companies still need to justify the continued bullishness of their stocks.